

Mixed ligand palladium(II) complexes of *N*-hydroxymethylsaccharin (Sac-CH₂OH): synthesis, characterization and biological studies

Subhi A. Al-Jibori¹ · Ahmed S. Al-Janabi² · Sucharita Basak-Modi³ · Samar S. Mohamed¹ · Harry Schmidt⁴

Received: 5 August 2015 / Accepted: 21 September 2015
© Springer International Publishing Switzerland 2015

Abstract Reaction of Na₂PdCl₄ with two equivalents of *N*-hydroxymethylsaccharin (Sac-CH₂OH) in the presence of NEt₃ afforded trans-[Pd(κ²-Sac-CH₂O)₂]. Further reaction of [Pd(κ²-Sac-CH₂O)₂] with one equivalent of diphosphine (L₂), Ph₂P(CH₂)_nPPh₂, (*n* = 1, dppm; 2, dppe and 3, dppp), Ph₂P(S)(CH₂)P(S)Ph₂ (dppmS₂) or Ph₂P(O)(CH₂)₂P(O)Ph₂ (dppeO₂) afforded mixed ligand complexes [Pd(κ¹-Sac-CH₂O)₂(L₂)], while reaction with two equivalents of Ph₃P, Ph₃PO or Ph₃PS (L) gave *trans*-[Pd(κ¹-Sac-CH₂O)₂(L)₂]. The *N*-hydroxymethylsaccharinate anion acts as a monodentate ligand, coordinating to the palladium center through the hydroxymethyl oxygen atom. The complexes were characterized by physico-chemical and spectroscopic methods. In addition, the free ligand *N*-hydroxymethylsaccharin and some of the complexes were screened *in vitro* for antibacterial activity.

Introduction

Saccharin (1,2-benzisothiazol-3(2*H*)-one-1,1-dioxide or *o*-benzosulfimide, Hsac) is known as a noncaloric artificial sweetener. Its coordination chemistry has been extensively

studied over the years [1–14]. Although for many years it was a suspected carcinogen in rats [15, 16], in the 1990s it was removed from the list of potential human carcinogens [17]. Palladium and platinum saccharinate complexes [7–14] have attracted interest primarily because of their biological properties. Complexes of saccharine derivatives have not been well studied; however, there is a recent report on the synthesis of *N*-substituted saccharine derivatives and their biological activity with respect to selective inhibition of human carbonic anhydrase [18].

In continuation of our recent studies with Pd(II) complexes [7, 19–21], herein we describe the preparation of mixed-ligand saccharinate derivative complexes with phosphines as co-ligands. *N*-hydroxymethylsaccharin (Sac-CH₂OH) was readily prepared (Scheme 1) and its reactions with Na₂PdCl₄ and phosphines gave rise to the complexes [Pd(κ¹-Sac-CH₂O)₂(L)_n] (*n* = 1 or 2) in high yields. These complexes were characterized by spectroscopic methods. In addition, the phosphine derivative complexes were screened for activity against several bacterial strains and showed some antibacterial effects compared with the parent compound.

Experimental

Materials and methods

All chemicals and solvents used in this work were commercial products and were used without further purification. *N*-hydroxymethylsaccharin was synthesized according to the literature method [22]. IR spectra were recorded in the 4000–200 cm⁻¹ range on a Bruker Tensor 28 spectrometer with a Platinum ATR unit. Melting points were measured on an Electrothermal 9300 melting point


✉ Subhi A. Al-Jibori
subhi_aljibori@yahoo.com

¹ Department of Chemistry, College of Science, University of Tikrit, Tikrit, Iraq

² Department of Chemistry, College of Veterinary Medicine, University of Tikrit, Tikrit, Iraq

³ Department of Chemistry, University College London, 20 Gordon Street, London WC1H 0AJ, UK

⁴ Institut für Chemie, Martin-Luther-Universität, Halle-Wittenberg, Kurt-Mothes-Str. 2, 06120 Halle, Germany



Scheme 1 Preparation of Sac-CH₂OH

apparatus. Elemental analysis was carried out on a CHN analyzer type 1106 Carlo-Erba. The ¹H and ¹³C NMR spectra were recorded on Varian unity 400 and Gemini 200 spectrometers, respectively, with *d*⁶-DMSO as solvent. ³¹P NMR spectra were recorded on a Gemini 200 spectrometer with *d*⁶-DMSO and CDCl₃ as solvents and H₃PO₄ (85 %) as an external reference. The NMR spectra are reported in ppm. The NMR spectra and elemental analysis were carried out at Al-Bayt University-Jordan and Institute für Anorganische Chemie, Martin-Luther-Universität, Halle, Germany. *N*-hydroxymethylsaccharin (Sac-CH₂OH) was characterized as follows. White prisms. Anal. Calc. for C₈H₇NO₄S; C, 45.1; H, 3.3; N, 6.6, Found: C, 45.1; H, 3.4; N, 6.8 %. IR (KBr): 3290 m ν(O–H); 3093 ν(C–H); 2975 ν(C–H); 1747 ν(C=O); 1595 ν(C=C); 1458 ν(C–N); 1340 ν_{asy}(SO₂); 1184 ν_{sy}(SO₂) cm⁻¹. ¹H NMR (*d*⁶-DMSO): δ 8.28 (dd, 1H, H4, ³J(HH) = 7.8 Hz, Ph); 8.12 (dd, 1H, H7, ³J(HH) = 7.8 Hz, Ph); 8.05 (td, 1H, H5, ³J(HH) = 8.8 Hz, ⁴J(HH) = 1.2 Hz, Ph); 7.99 (td, 1H, ³J(HH) = 8.4 Hz, ⁴J(HH) = 1.3 Hz, H6); 6.74 (bs, 1H, OH); 5.18 (s, 2H, OCH₂). ¹³C NMR (*d*⁶-DMSO): δ 161.49 (CO), 140.21 (C3, Ph), 136.09 (C8, Ph), 134.51 (Ph), 129.19 (Ph), 125.09 (Ph), 121.99 (Ph), 68.51 (CH₂). Melting point: 134–136 °C (lit. 135–137) [22]. For antibacterial studies, the test organisms were grown on nutrient agar medium in petri plates [23–26]. Fresh solutions of the compounds were prepared in DMSO and used to soak filter paper disks of 5 mm diameter and 1 mm thickness. The disks were placed on previously seeded plates and then incubated at 37 °C, and the diameter of the inhibition zone around each disk was measured after 24 h (Table 1).

Table 1 A diameter of inhibition zone (mm) of 100 μg/ml of free Sac-CH₂OH and its complexes

Compound	Bacterial species			
	<i>E. coli</i>	<i>B. subtilis</i>	<i>P. aeruginosa</i>	<i>S. aureus</i>
Sac-CH ₂ OH	23	35	75	>100
1	19	65	20	50
2	07	10	34	35
3	43	27	05	25
6	>100	43	50	20
Ofloxacin	10	05	05	05
Ciprofloxacin	05	05	05	05

Preparation of complex 1



A warm solution of Sac-CH₂OH (0.145 g, 0.68 mmol) in EtOH (10 ml) containing a few drops of Et₃N was added to a solution of Na₂PdCl₄ (0.10 g, 0.34 mmol) in EtOH (15 ml). The mixture was stirred for 15 min at room temperature. The brown-yellow precipitate was filtered off, washed with ethanol and dried under vacuum to afford [Pd(κ²-Sac-CH₂O)₂].2H₂O (**1**) (Scheme 2). Brown yellow solid. Yield: 0.13 g (68 %). Anal. Calc. for C₁₆H₁₆N₂O₁₀.PdS₂: C, 33.9; H, 2.8; N, 4.9; Found, C, 34.1; H, 2.9; N, 5.0 %. IR (KBr): 3521 ν(O–H) for H₂O; 3087 ν(=C–H); 2985 ν(C–H); 1673 ν(C=O); 1593 ν(C=C); 1294 ν_{asy}(SO₂); 1174 ν_{sy}(SO₂); 540 ν(Pd–O) cm⁻¹. ¹H NMR (*d*⁶-DMSO): δ 7.69 (d, 2H, ³J(HH) = 8.6 Hz, H1); 7.54 (t, 2H, ³J(HH) = 7.9 Hz, H2); 7.30 (d, 2H, ³J(HH) = 8.63 Hz, H4); 6.97 (t, 2H, ³J(HH) = 7.8 Hz, H3); 5.25 (s, 4H, OCH₂). ¹³C NMR (*d*⁶-DMSO): δ 171.60 (CO), 140.70, 136.11, 133.64, 126.03, 122.89, 61.39 (CH₂). Melting point: 180 °C (decomposes).

Preparation of complex 2

A solution of dpmm (0.131 g, 0.34 mmol) in CHCl₃ (10 ml) was added to a suspension of complex **1** (0.145 g, 0.34 mmol) in CHCl₃ (15 ml). The resulting yellow solution formed was stirred at 30 °C for 3 h and then left for slow evaporation at room temperature. The yellow precipitate was filtered off, washed with CHCl₃ and dried under vacuum (Scheme 3). The related complexes [Pd(Sac-CH₂O)₂(dppe)] (**3**), [Pd(Sac-CH₂O)₂(dppp)] (**4**), [Pd(Sac-CH₂O)₂(dppmS₂)] (**5**) and [Pd(Sac-CH₂O)₂(-dppeO₂)] (**6**) were prepared and isolated in a similar manner.

[Pd(Sac-CH₂O)₂(dppm)] (**2**): Yellow solid. Yield: 0.236 g (76 %). Anal. Calc. for C₄₁H₃₄N₂O₈P₂PdS₂, C, 53.8; H, 3.7; N, 3.1; Found, C, 53.6; H, 3.9; N, 3.0 %. IR (KBr): 3546, 3454 ν(O–H) for H₂O; 3056 ν(=C–H); 2997 ν(C–H); 1695 ν(C=O); 1587 ν(C=C); 1294 ν_{asy}(SO₂); 1164 ν_{sy}(SO₂); 503 ν(P–C); 530 ν(Pd–O) cm⁻¹. ¹H NMR (*d*⁶-DMSO): δ 8.46–7.37 (m, 28H, Ar), 5.06 (s, 4H, OCH₂), 2.95 (s, 2H, CH₂). ¹³C NMR (*d*⁶-DMSO): δ 163.78, 140.70, 136.11, 133.64, 130.58, 126.88, 122.89, 63.76. ³¹P NMR (*d*⁶-DMSO): δ 29.37. Melting point: 196–199 °C.

[Pd(Sac-CH₂O)₂(dppe)] (**3**): Yellow solid. Yield: 84 %. Anal. Calc. for C₄₂H₃₆N₂O₈P₂PdS₂, C, 54.3; H, 3.9; N, 3.0; Found, C, 54.4; H, 3.8; N, 3.13 %. IR (KBr): 3064 ν(=C–H); 2929 ν(C–H); 1699 ν(C=O); 1585 ν(C=C); 1292 ν_{asy}(SO₂); 1143 ν_{sy}(SO₂); 507 ν(P–C); 530 ν(Pd–O) cm⁻¹. ¹H NMR (*d*⁶-DMSO): δ 7.27–7.66 (m, 28H, Ar), 5.17 (s, 4H, OCH₂), 3.02 (t, 4H, ³J(HH) = 7.9 Hz, CH₂). ¹³C NMR (*d*⁶-DMSO): δ 161.89, 140.89, 136.11, 132.89,

Scheme 2 Preparation of complex **1****Scheme 3** Preparation of complexes **2–9**

130.58, 126.93, 122.89, 63.76. ^{31}P NMR (d^6 -DMSO): δ 44.46. Melting point: 204–208 °C (decomposes).

[Pd(Sac-CH₂O)₂(dppp)] (**4**): Yellow solid. Yield: 80 %. Anal. Calc. for C₄₅H₄₄N₂O₉P₂PdS₂, C, 54.6; H, 4.5; N, 2.8; Found, C, 54.3; H, 4.2; N, 3.0 %. IR (KBr): 3083 ν (C–H); 2987 ν (C–H); 1701 ν (C=O); 1591 ν (C=C); 1302 $\nu_{\text{asy}}(\text{SO}_2)$; 1143 $\nu_{\text{sy}}(\text{SO}_2)$; 480 ν (P–C); 526 ν (Pd–O) cm^{-1} . ^1H NMR (d^6 -DMSO): δ 8.28–7.96 (m, 28H, Ar); 5.18 (s, 4H, OCH₂); 2.88 (t, 4H, $^3J(\text{HH}) = 8.1$ Hz, CH₂); 1.90 (b, 2H, CH₂). ^{13}C NMR (d^6 -DMSO): δ 164.0, 140.10, 135.36, 132.95, 131.13, 128.40, 122.56, 61.95. ^{31}P NMR (d^6 -DMSO): δ 27.67. Melting point: 158–161 °C.

[Pd(Sac-CH₂O)₂(dppmS₂)] (**5**): Yellow solid. Yield: 41 %. Anal. Calc. for C₆₆H₅₆N₂O₈P₄PdS₆, C, 55.5; H, 3.9; N, 1.9. Found: C, 55.9; H, 4.2; N, 2.2 %. IR (KBr): 3053 ν (C–H); 2918 ν (C–H); 1703 ν (C=O); 1529 ν (C=C); 1290 $\nu_{\text{asy}}(\text{SO}_2)$; 1126 $\nu_{\text{sy}}(\text{SO}_2)$; 499 ν (P–C); 545 ν (Pd–O) cm^{-1} . ^1H NMR (CDCl₃): δ 7.10–8.01 (m, 28H, Ar), 5.20 (bs, 4H, OCH₂), 1.71 (s, 2H, CH₂) ppm. ^{13}C NMR (d^6 -DMSO): δ 162.23, 140.47, 136.0, 132.65, 131.07, 126.98, 122.33,

62.13. ^{31}P NMR (d^6 -DMSO): δ 24.47. Melting point: 268–272 °C (decomposes).

[Pd(Sac-CH₂O)₂(dppeO₂)] (**6**): Yellow solid. Yield: 81 %. Anal. Calc. for C₄₂H₃₆N₂O₁₀P₂PdS₂: C, 52.5; H, 3.8; N, 2.9; Found, C, 52.6; H, 3.6; N, 3.1 %. IR (KBr): 3100 ν (C–H), 2981 ν (C–H), 1691 ν (C=O), 1587 ν (C=C), 1296 $\nu_{\text{asy}}(\text{SO}_2)$, 1163 $\nu_{\text{sy}}(\text{SO}_2)$, 500 ν (P–C), 526 ν (Pd–O) cm^{-1} . ^1H NMR (d^6 -DMSO): δ 7.12–7.71 (m, 28H, Ar), 5.04 (s, 4H, OCH₂), 3.08 (t, 4H, $^3J(\text{HH}) = 8.0$ Hz, CH₂). ^{13}C NMR (d^6 -DMSO): δ 162.67, 141.09, 135.89, 132.83, 131.06, 125.87, 123.67, 61.45. ^{31}P NMR (d^6 -DMSO): δ 35.48. Melting point: 244–246 °C (decomposes).

Preparation of complex **7**

A solution of PPh₃ (0.178 g, 0.68 mmol) in CHCl₃ (10 ml) was added to a suspension of complex **1** (0.193 g, 0.34 mmol) in CHCl₃ (15 ml) with stirring. The yellow solution so formed was stirred at room temperature for 2 h, then left to evaporate at room temperature. The yellow

precipitate was filtered off, washed with diethyl ether followed by CHCl_3 and dried under vacuum (Scheme 3). The complexes $[\text{Pd}(\text{Sac-CH}_2\text{O})_2(\text{O=PPh}_3)_2]$ (**8**) and $[\text{Pd}(\text{Sac-CH}_2\text{O})_2(\text{S=PPh}_3)_2]$ (**9**) were prepared and isolated by similar procedures.

$[\text{Pd}(\text{Sac-CH}_2\text{O})_2(\text{PPh}_3)_2]$ (**7**): Yellow solid. Yield: 0.32 g (76 %). Anal. Calc. for $\text{C}_{52}\text{H}_{42}\text{N}_2\text{O}_8\text{P}_2\text{PdS}_2$: C, 59.2; H, 4.0; N, 2.6; Found, C, 59.4; H, 4.2; N, 2.4 %. IR (KBr): 3091 $\nu(\text{C-H})$; 2972 $\nu(\text{C-H})$; 1692 $\nu(\text{C=O})$; 1571 $\nu(\text{C=C})$; 1290 $\nu_{\text{asy}}(\text{SO}_2)$; 1155 $\nu_{\text{sy}}(\text{SO}_2)$; 522 $\nu(\text{P-C})$; 533 $\nu(\text{Pd-O}) \text{ cm}^{-1}$. ^1H NMR (d^6 -DMSO): δ 8.28–7.09 (m, 38H, Ar), 5.09 (s, 4H, OCH_2). ^{13}C NMR (d^6 -DMSO): δ 163.60, 140.70, 136.11, 132.98, 130.58, 125.76, 122.89, 62.65. ^{31}P NMR (d^6 -DMSO): δ 18.05. Melting point: 254–259 °C (decomposes).

$[\text{Pd}(\text{Sac-CH}_2\text{O})_2(\text{O=PPh}_3)_2]$ (**8**): Brown-yellow. Yield: 81 %. Anal. Calc. for $\text{C}_{52}\text{H}_{42}\text{N}_2\text{O}_{10}\text{P}_2\text{PdS}_2$: C, 57.4; H, 3.9; N, 2.6; Found, C, 57.5; H, 3.9; N, 2.7 %. IR (KBr): 3093 $\nu(\text{C-H})$; 2933 $\nu(\text{C-H})$; 1696 $\nu(\text{C=O})$; 1604 $\nu(\text{C=C})$; 1288 $\nu_{\text{asy}}(\text{SO}_2)$; 1157 $\nu_{\text{sy}}(\text{SO}_2)$; 522 $\nu(\text{P-C})$; 546 $\nu(\text{Pd-O}) \text{ cm}^{-1}$. ^1H NMR (d^6 -DMSO): δ 8.06–7.05 (m, 38H, Ar), 5.73 (s, 4H, OCH_2). ^{13}C NMR (d^6 -DMSO): δ 163.93, 140.04, 136.49, 132.79, 130.94, 125.64, 121.92, 64.37. ^{31}P NMR (d^6 -DMSO): δ 43.23. Melting point: 189–192 °C.

$[\text{Pd}(\text{Sac-CH}_2\text{O})_2(\text{S=PPh}_3)_2]$ (**9**): Dark yellow. Yield: 76 %. Anal. Calc. for $\text{C}_{52}\text{H}_{42}\text{N}_2\text{O}_{10}\text{P}_2\text{PdS}_4$: C, 55.8; H, 3.8; N, 2.5; Found, C, 55.8; H, 3.9; N, 2.7 %. IR (KBr): 3087 $\nu(\text{C-H})$; 2873 $\nu(\text{C-H})$; 1698 $\nu(\text{C=O})$; 1612 $\nu(\text{C=C})$; 1292 $\nu_{\text{asy}}(\text{SO}_2)$; 1151 $\nu_{\text{sy}}(\text{SO}_2)$; 503 $\nu(\text{P-C})$; 542 $\nu(\text{Pd-O}) \text{ cm}^{-1}$. ^1H NMR (d^6 -DMSO): δ 7.97–6.99 (m, 38H, Ar), 5.24 (s, 4H, OCH_2). ^{13}C NMR (d^6 -DMSO): δ 163.12, 141.11, 136.52, 132.79, 131.94, 125.68, 121.33, 64.56, 41.17. ^{31}P NMR (d^6 -DMSO): δ 17.44. Melting point: 260–262 °C (decomposes).

Results and discussion

In order to prepare the target phosphine derivative complexes, $[\text{Pd}(\kappa^1\text{-Sac-CH}_2\text{O})_2(\text{L})_n]$ ($n = 1, 2$), we first prepared the saccharine derivative complex with palladium(II). Thus, treatment of $\text{Na}_2[\text{PdCl}_4]$ with two equivalents of *N*-hydroxymethylsaccharin ($\text{Sac-CH}_2\text{OH}$) in the presence of NEt_3 afforded *trans*- $[\text{Pd}(\kappa^2\text{-Sac-CH}_2\text{O})_2]$ (**1**) in EtOH (Scheme 2). The parent Pd(II) complex was assigned as the *trans* isomer based primarily on its IR spectrum, which is relatively simple in accordance with the higher symmetry and also with other complexes of the type *trans*- $[\text{Pd}(\kappa^1\text{-Sac-CH}_2\text{O})_2(\text{L})_2]$ (see below). The hydroxymethylsaccharinate anion in complex **1** behaves as a bidentate ligand, coordinating through the carbonyl and CH_2O oxygen atoms. Evidence for this assignment comes from the IR spectrum of complex **1** which displayed

$\nu(\text{C=O})$ at 1673 cm^{-1} . The reaction of sac derivative complex (**1**) with different diphosphines in an equivalent ratio afforded $[\text{Pd}(\kappa^1\text{-Sac-CH}_2\text{O})_2(\text{L}_2)]$ (**2–6**) in 60–85 % yields, as illustrated in Scheme 3. The same reaction with monophosphines gives rise to *trans*- $[\text{Pd}(\kappa^1\text{-Sac-CH}_2\text{O})_2(\text{L})_2]$ (**7–9**) as yellow solids in 70–80 % yields. The $\text{Sac-CH}_2\text{O}^-$ in complexes **2–9** behaves as a monodentate ligand coordinated through the oxygen atom of the CH_2O^- group. This was deduced from the high frequency shift of $\nu(\text{C=O})$ from 1673 cm^{-1} for complex **1** to $1691\text{--}1701 \text{ cm}^{-1}$ in the spectra of complexes **2–9**. Complexes **1–9** are stable in DMSO or DMF solutions when kept at room temperature and showed no decomposition over a week as evident from their ^1H NMR spectra. However, they are unstable in hot DMSO or DMF solution, decomposing to black precipitates.

In order to determine the precise coordination sphere, we attempted to grow X-ray quality single crystals of these complexes by dissolving them in DMSO or DMF at room temperature with the addition of a few drops of EtOH or CHCl_3 . Unfortunately all these attempts were unsuccessful and no crystals suitable for X-ray diffraction studies were obtained.

Spectroscopic and analytical data are in full accordance with the proposed formulations. The ^1H NMR spectra of each complex displayed the expected signals for the saccharinate derivative as well as the phosphine ligands. The single peak observed in their ^{31}P NMR spectra confirmed symmetric coordination around the metal center in these complexes. The *N*-hydroxymethylsaccharinate anion coordinated to the palladium(II) center through hydroxymethyl oxygen in each of these complexes most likely in a square planar geometry.

Antibacterial activities

Antibacterial activities of the free ligand and its complexes were tested in vitro against the bacterial species *Escherichia coli*, *Bacillus subtilis*, *Pseudomonas aeruginosa* and *Staphylococcus aureus*.

The results of the antibacterial studies are summarized in Table 1. The standard error for the experiment was $\pm 0.002 \mu\text{g/ml}$, and the experiments were repeated three times under similar conditions. DMSO was used as negative control, and ofloxacin and ciprofloxacin were used as positive controls. The results show that the metal chelates are more active than the starting materials and the free ligand, as is frequently the case [26]. The $\text{Sac-CH}_2\text{OH}$ ligand shows good activity against the bacterial strain *E. coli* and *B. subtilis*, while all the complexes exhibit excellent in vitro antibacterial activities against both Gram-positive and Gram-negative organisms.

Conclusions

This work has shown that the synthesis of sac derivative complexes of the type $[\text{Pd}(\text{Sac-CH}_2\text{O})_2(\text{L})_n]$ containing various phosphine ligands is general and straightforward starting from $\text{Na}_2[\text{PdCl}_4]$ and readily prepared ligands. Further, the yields of each step are high, reactions can be carried out in air and product isolation is simple. However, crystallization of the synthesized complexes proved to be intractable. The complexes showed some antibacterial activities. Further syntheses of other transition metal complexes with this ligand are in progress.

Acknowledgments We thank Department of Microbiology, College of Veterinary Medicine, Tikrit University for the antibacterial study and Erasmus Mundus programme for a post-doctoral scholarship to S. B.-M.

References

1. Baran EJ, Yilmaz VT (2006) *Coord Chem Rev* 250:1980
2. Baran EJ (2005) *Quim Nova* 28:1
3. Falvello LR, Gomez J, Pascual I, Tomás M, Urriolabeitia EP, Schultz AJ (2001) *Inorg Chem* 40:4455
4. Deng RMK, Dillon KB, Goeta AE, Mapolelo M, Shepherd HJ (2009) *Inorg Chim Acta* 362:5109
5. Guney E, Yilmaz VT, Kazak C (2010) *Polyhedron* 29:1285
6. Guney E, Yilmaz VT, Sengul A, Buyukgunor O (2010) *Inorg Chim Acta* 363:438
7. Al-Jibori SA, Al-Jibori MHS, Hogarth G (2013) *Inorg Chim Acta* 398:117
8. Ulukaya E, Ari F, Dimas K, Ikitimur EI, Guney E, Yilmaz VT (2011) *Eur J Med Chem* 46:4957
9. Guney E, Yilmaz VT, Ari F, Buyukgunor O, Ulukaya E (2011) *Polyhedron* 30:114
10. Guney E, Yilmaz VT, Buyukgunor O (2010) *Inorg Chim Acta* 363:2416
11. Guney E, Kaya Y, Yilmaz VT, Gumus S (2011) *Spectrochim Acta Part A* 79:1171
12. Guney E, Yilmaz VT, Buyukgunor O (2011) *Polyhedron* 30:1968
13. Henderson W, Nicholson BK, McCaffrey LJ (1999) *Inorg Chim Acta* 285:145
14. Henderson W, Nicholson BK, Chung DC, *Crystallogr Acta* (2002) Sect E 58:m432
15. Price JM, Biava CG, Oser BL, Vogin EE, Steinfeld J, Ley HL (1970) *Science* 167:1131
16. Weihrauch MR, Diehl V, Bohlen H (2001) *Mediz Klin* 96:670
17. Chappel CI (1992) *Reg Toxicol Pharm* 15:253
18. Ascenzio MD, Carradori S, Monte CD, Secci D, Ceruso M, Supuran Claudiu T (2014) *Bioorg. Med Chem* 22:1821
19. Al-Jibori SA, Al-Nassiry AIA, Hogarth G, Salassa L (2013) *Inorg Chim Acta* 398:46
20. Al-Jibori SA, Al-Jibori QKA, Schmidt H, Merzweiler K, Wagner C, Hogarth G (2013) *Inorg Chim Acta* 402:69
21. Al-Jibori SA, Al-Nassiry RAQ, Al-Jibori GHH, Merzweiler K, Wagner C, Schmidt H, Basak-Modi S, Hogarth G (2014) *Trans Met Chem* 39:735
22. Siddiqi WA, Ahmed S, Khan IU, Siddiqi HL, Ahmed VU (2007) *J Chem Soc Pak* 29:44
23. Bauer A, Kirby WM, Sherris JC, Truck M (1966) *Am J Clin Pathol* 45:493
24. Wahed MG, Bayoumi HA, Mohamme MI (2003) *Bull Korean Chem Soc* 24:1313
25. Makode JT, Yaul AR, Bhadange SG, Aswar AS (2009) *Russ J Inorg Chem* 54:1372
26. Priya NP, Arunachalam SV, Sathya N, Chinnusamy V, Jayabalakrishnan C (2009) *Transition Met Chem* 34:437